ClinicalTrials.gg
RecruitingNCT06905340NORAUpdated Jun 8, 2025

Guiding Opioid Administration by Nociception Level Index (NOL) in Patients With Regional Anesthesia

An interventional study of NOL (Nociception Level Index) and Control (Standard treatment) in Nociceptive Pain, Pain, Postoperative and Analgesia, Postoperative, sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-08.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

General anesthesia consists of a combination of hypnotic drugs to achieve unconsciousness and opioid analgesics to ensure antinociception. An alternative approach to the intraoperative administration of high-potency opioids to achieve antinociception during surgery is combining general anesthesia with regional anesthesia. Modern general anesthesia aims to avoid an overdose of opioid analgesics and reduce side effects of opioid administration. Quality and safety of general anesthesia are of major clinical importance and can be improved by adjusting the opioid analgesics to the optimal individual dose needed.

In current clinical practice, opioid dosage is usually determined by clinical judgment. However, different monitoring devices estimating the effect of nociception during unconsciousness have become commercially available. One of the most recent commercially available nociception indices is the Nociception Level Index (NOL). Until today, there is conflicting evidence on whether guiding sufentanil administration by NOL monitoring, which is the intended use of the nociception index, affects postoperative pain level in the postanesthesia care unit (PACU), the amount of postoperatively administered opioids, and the quality of postoperative recovery in patients with a combination of general and regional anesthesia. This study aims to investigate the clinical performance of intraoperative NOL monitoring and determine whether guiding sufentanil administration by NOL monitoring - compared to routine care - reduces either postoperative pain level in the PACU, postoperative opioid consumption in the PACU or postoperative opioid consumption in the first 24 hours after the operation in patients having trauma and orthopedic surgery with combined general and regional anesthesia.

Read the detailed description

Modern general anesthesia aims to treat nociception induced by surgical stimulation while avoiding an overdose of opioid analgesics and reducing side effects of opioid administration.

Underdosing of opioids during surgery can lead to nociception with increased sympathetic tone, elevated levels of stress hormones, unintended patient movement as well as increased postoperative pain. On the other hand, overdosing of opioids can lead to negative side effects such as nausea and vomiting, arterial hypotension, immunosuppression, prolonged recovery times, postoperative delirium and an increase in postoperative pain by opioid-induced hyperalgesia. Anesthesiologists therefore aim to strike the balance between an effective and long-lasting perioperative anesthesia/analgesia, and keeping the intra- and postoperative opioid dosage as high as needed, but as low as possible to reduce adverse effects. An alternative approach to the intraoperative administration of high-potency opioids for achieving antinociception during surgery is combining general anesthesia with regional anesthesia. By combining the two, the anesthesiologists aim to reduce intraoperative and postoperative opioid administration without compromising reflex control of the autonomous nervous system, immobility of the surgical site without patients' defensive movements, a pain-free awakening after surgery and a pain-free postoperative recovery.

Critically, the quality of regional anesthesia cannot be assessed during general anesthesia by the anesthesiologist, and patients cannot express their pain themselves. Therefore, anesthesiologists tend to administer a certain calculated opioid dose during the operation. Whether this calculated opioid administration is essential for a sufficient anesthesia or is an unnecessary overdose cannot be assessed by the anesthesiologist. To this day, there has been no measurement tool that could estimate the effectiveness of regional anesthesia and the absence of nociception during general anesthesia combined with regional anesthesia.

In recent years, different monitoring devices estimating the effect of nociception during unconsciousness have become commercially available. Such monitoring devices should help physicians to choose the right dose of opioid analgesics during general anesthesia with nociception indices. Among those, the Nociception Level Index (NOL) developed by Medasense Biometrics Ltd, Ramat Yishai, Israel is one of the most promising nociception indices regarding a possible improvement of postoperative patient recovery. This commercially available nociception index has been developed for guiding intraoperative sufentanil administration, has received CE certification for the EU area and an approval by the FDA. The NOL is based on the four physiological parameters heart rate variability, pulse plethysmographic amplitude, skin conductance and skin temperature, which are all measured with a non-invasive finger sensor. A proprietary algorithm generates the NOL from the changes in the four parameters over time using a non-linear random forest regression method through machine learning.

The dimensionless index is presented on a scale from 0 (low sympathetic tone) to 100 (high sympathetic tone) caused by nociception during surgery. According to the manufacturer, a value above 25 indicates a clinically relevant nociceptive response to noxious stimuli while a value below 10 during an operation lasting for more than 2 minutes indicates excessively high analgesia.

Nevertheless, the current literature remains inconclusive about the impact of NOL-guided opioid administration. There is conflicting evidence on the anesthesia-related outcome parameters postoperative pain level, intraoperatively and postoperatively administered amount of opioids, postoperative short-term recovery, and long-term outcome. No study has yet evaluated whether one may estimate the effectiveness of regional anesthesia during general anesthesia by monitoring the intraoperative nociception with the NOL. If the NOL was able to assess nociception, NOL-guided opioid administration could possibly reduce postoperative pain level in the PACU, postoperative opioid consumption in the PACU and postoperative opioid consumption in the first 24 hours after the operation on the ward. Such a reduction of the perioperative opioid dose would constitute a clinically important benefit for patients when considering the previously detailed risks of overdosing opioid analgesics as well as the context of perioperatively developed opioid addiction. Nevertheless, it remains unknown whether guiding sufentanil administration by NOL monitoring affects the administered amount of intraoperative and postoperative opioid consumption, immediate postoperative pain in the PACU and the quality of postoperative recovery, which is the intended use of the nociception index, in patients with a combination of general and regional anesthesia.

This prospective, randomized controlled trial aims to investigate the clinical performance of intraoperative NOL monitoring and determine whether guiding sufentanil administration by NOL monitoring - compared to routine care - reduces either postoperative pain level in the PACU, postoperative opioid consumption in the PACU or postoperative opioid consumption in the first 24 hours after the operation in patients undergoing trauma and orthopedic surgery with a combination of general and regional anesthesia. The hypothesis tested in the present study is that in patients having trauma and orthopedic surgery with a combination of general and regional anesthesia, administration of sufentanil guided by NOL monitoring reduces either postoperative pain level in the PACU, postoperative opioid consumption in the PACU or postoperative opioid consumption in the first 24 hours after the operation compared to routine care.

02

Conditions studied

  • Nociceptive Pain
  • Pain, Postoperative
  • Analgesia, Postoperative
  • Anesthesia Recovery Period
  • Opioid Use

Keywords

  • General anesthesia
  • Regional anesthesia
  • Analgesia Monitoring
  • Opioids
03

In context

Nociceptive Pain

97 studies on the registry are indexed under Nociceptive Pain; 19 are open to participants now.

This study's planned enrollment of 240 is above the median of 62 across 63 interventional studies indexed under Nociceptive Pain.

Browse Nociceptive Pain studies →

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 416 studies on the registry; 86 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing elective trauma or orthopedic surgery with a combination of general and regional anesthesia

Exclusion criteria

Exclusion Criteria:

  • Preexisting therapy with cardiac glycosides or pacemakers
  • Cardiac arrhythmia (atrial fibrillation, atrioventricular block > I°)
  • Chronic opioid misuse
  • Intraoperative treatment with ketamine, beta-adrenergic agonists, or clonidine
  • Serious peripheral or cardiac autonomic neuropathy
  • Inability to specify the postoperative pain level
  • Postoperative treatment in an ICU
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    NOL (Nociception Level Index)

    Opioid administration (sufentanil) guided by the Nociception Level Index (NOL) derived from photoplethysmography, galvanic skin conductance, and the measurement of skin temperature performed by the device PMD-200 Nociception Monitor from the manufacturer Medasense Biometrics Ltd, Ramat Yishai, Israel. Included in the monitoring system is software that continuously calculates the NOL from normalized heart rate variability, pulse plethysmographic amplitude, skin conductance, and skin temperature derived from a finger sensor. The numerical index ranges from 0 (low sympathetic tone) to 100 (high sympathetic tone). A NOL score between 10 and 25 has been proposed as the target range based on which to guide opioid analgesics dosage. 5 µg sufentanil will be administered if the NOL score exceeds 25 for more than 60 seconds. The sufentanil boluses may be repeated to keep NOL between 10-25 accordingly.

    Procedure: NOL (Nociception Level Index)

  • Active comparator
    Control

    Opioid administration (sufentanil) based on standard clinical practice where attending anesthesiologists are advised to administer 5 µg sufentanil if signs of inadequate anesthesia are present. Given adequate hypnosis (BIS 40-60), these signs include hypertension (MAP\>120% of baseline or \>100mmHg), tachycardia (HR\>120% of baseline or \>90/min), somatic arousal (coughing, chewing, grimacing) and somatic response (purposeful movement). The patient-specific baseline is defined as the average of three consecutive post-induction, pre-surgery MAP and HF values. The time elapsed between 5µg doses of sufentanil is up to the anesthesiologist's discretion.

    Other: Control (Standard treatment)

Interventions

  • ProcedureNOL (Nociception Level Index)

    Elective surgery in patients having trauma and orthopedic surgery with a combination of general and regional anesthesia. Opioid titration is guided by NOL during general anesthesia in the experimental arm.

  • OtherControl (Standard treatment)

    Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist

06

What researchers measure

Primary outcomes

  1. Postoperative pain level in the PACU

    Compares the proportion of postoperative pain level (NRS=0 vs. NRS\>0) in the postanesthesia care unit (PACU) between the groups.

    Time frame: 1 day

  2. Postoperative administration of opioids during the PACU stay

    Compares the proportion of postoperative administration of opioids during the PACU stay (none vs. any) between the groups.

    Time frame: 1 day

  3. Postoperative administration of opioids in the first 24 hours after the operation

    Compares the proportion of postoperative administration of opioids in the first 24 hours after the operation (none vs. any) between the groups.

    Time frame: 2 days

Secondary outcomes

  1. Intraoperative sufentanil consumption

    Compares intraoperative sufentanil consumption \[μg/kg/min\] between the groups.

    Time frame: 1 day

  2. Intraoperative norepinephrine consumption

    Compares intraoperative cumulative dose of norepinephrine consumption \[μg/kg/min\] between the groups.

    Time frame: 1 day

  3. Time to extubation

    Compares the time from end of narcotics to extubation \[min\] between the groups.

    Time frame: 1 day

  4. Postoperative nausea and vomiting (PONV)

    Compares the incidence of postoperative nausea and vomiting (PONV) (%) between the groups.

    Time frame: 1 day

  5. PACU stay

    Compares the length of stay in the postanesthesia care unit (PACU) (min) between the groups.

    Time frame: 1 day

  6. Postoperative pain level 24 hours after the operation

    Compares the postoperative pain level at rest 24 hours after the operation (NRS 0-10) between the groups.

    Time frame: 2 days

  7. Quality-of-Recovery QoR-15 Score

    Compares the quality of postoperative recovery measured by the Quality-of-Recovery QoR-15 Score (0-120 points) 24 hours after the operation between the groups.

    Time frame: 2 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2025, 7 months after the start.

Of 38 non-industry interventional studies with no phase under Nociceptive Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 32. This study's planned 7 months is below that.

Counting every sponsor, half of 43 studies reached it within 8 months; a quarter within 3 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 1, 2025
StartActual
May 12, 2025
Primary completionEst.
Dec 2025
CompletionEst.
Jan 2026
Last update
Jun 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06905340
Responsible party
Sponsor
First posted
Apr 1, 2025
Start date
May 12, 2025
Primary completion
Dec 2025 (estimated)
Completion
Jan 2026 (estimated)
Last update
Jun 8, 2025

Study contacts

Rainer Nitzschke, MD
Contact
r.nitzschke@uke.de
+4915222815884
Annika Zoller
Contact
ana-sek@uke.de
+49040741052415
Rainer Nitzschke, MD
principal investigator · Universitätsklinikum Hamburg-Eppendorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion